

## PURPOSE OF BILL: HB 1079

To mandate coverage for genetic testing for an inherited gene mutation and evidence-based cancer imaging for certain individuals, not subject to deductible, copay, or coinsurance limits.

## ACTUARIAL STATEMENT

The Fiscal Impact Statement was prepared according to generally accepted actuarial principles and practices, in compliance with ACT 112. The Statement provides an estimate of the financial and actuarial effect of the proposed change(s) on the Plans, if possible. The Statement makes no comment or opinion with regard to the merits of the measure for which the Statement is prepared; however, any identified technical or mechanical defects have been noted.

We have reviewed the input and results of our analysis for reasonableness and relied upon the data and information provided by the Plans and their Claims Processing Contractors.

A handwritten signature in black ink, appearing to read "Patrick Klein".

3/19/2025

---

Patrick Klein, FSA, MAAA  
Vice President, Segal

---

Date

A handwritten signature in black ink, appearing to read "Matthew Kersting".

3/19/2025

---

Matthew Kersting, FSA, MAAA  
Vice President, Segal

---

Date

## PROJECTED COSTS

Plan	Plan Design Change	Estimated Impact
EBD	No Change	No impact

## PRICING APPROACH AND COMMENTS

House Bill 1079 requires coverage for genetic testing for an inherited gene mutation and evidence-based cancer imaging for certain individuals, and prohibits it being a subject to annual deductible, copayment, or coinsurance.

The amendment made to this bill on March 17, 2025 states that the requirements of HB 1079 do not apply to EBD and therefore there will be no financial impact.